Atlas Trials

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Clinical trial NCT04279938 · WITHDRAWN

Trial details

NCT number
NCT04279938
Sponsor
Royal Marsden NHS Foundation Trust
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Start date
2018-09-01
Primary completion
2020-03-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.